

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
B	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>	2015
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
G	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Date: 14 April 2020

State Party to the Convention: Republic of Estonia

Date of ratification/accession to the Convention: 21 June 1993

National point of contact: Ms Terje Raadik, Security Policy and Arms Control Division, Political Department, Ministry of Foreign affairs of the Republic of Estonia

Islandi väljak 1

15049 Tallinn

Phone: (+372) 6377 120;

E-mail: terje.raadik@mfa.ee

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Estonia do not possess a facility meeting criteria for BSL 4.

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents¹ on a State Party's territory:

Biosafety level 3 ²	yes
--------------------------------	-----

BSL 3 laboratories in Estonia: Joint Laboratories of Tartu University Clinics, Institute of Biomedicine and Translational Medicine of Tartu University, Laboratory of Communicable Diseases of Estonian Health Board, Synlab/Estonia, Microbiology Laboratory of North-Estonia Regional Hospital, Veterinary & Food Laboratory, Laboratory for Mycobacteriosis of University of Life Sciences.

Part 2

Exchange of information on national biological defence research and development programmes

Estonia is not running national biological defence research and development programmes.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques,

¹ Microorganisms pathogenic to humans and/or animals

² In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

aerobiology, detection, treatment, toxicology, physical protection, decontamination and other related research.

No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

Non

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Non

Confidence-Building Measure "B"

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

Form B

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern³

There were no cases for the 2019 reporting period on outbreaks of infectious diseases and similar occurrences caused by toxins that seem to deviate from the normal pattern. We report the information with respect to infectious diseases of humans covering the years 2012-2019 in Estonia.

Diseases	Number of cases							
	2012	2013	2014	2015	2016	2017	2018	2019
Acquired immunodeficiency syndrome (AIDS)	36	24	20	19	41	20	25	28
Human immunodeficiency virus infection (HIV)	315	325	291	270	229	219	190	178
Anthrax	0	0	0	0	0	0	0	0
Avian influenza A/H5 or A/H5N1 in humans	0	0	0	0	0	0	0	0

³ See paragraph 2 of the chapeau to Confidence-Building Measure B.

Diseases	Number of cases							
	2012	2013	2014	2015	2016	2017	2018	2019
Botulism	0	0	0	0	0	0	3	0
Brucellosis	0	0	0	0	0	0	1	1
Campylobacteriosis	268	385	308	364	382	347	411	348
Chlamydia infection, gen.	1596	1625	1524	1351	1275	1139	983	1090
Cholera	0	0	0	0	0	0	0	0
Creutzfeldt-Jakob disease (sporadic)	0	1	4	0	0	0	1	1
Cryptosporidiosis	0	0	2	4	1	0	3	0
Diphtheria	0	0	0	0	0	0	0	0
Echinococcosis	3	3	1	0	0	1	0	2
Escherichia coli infection (STEC/VTEC)	3	8	6	8	5	3	7	6
Giardiasis	254	195	221	181	187	161	107	121
Gonorrhoea	217	136	136	121	96	58	49	81
<i>Haemophilus influenzae</i> infection	43	40	36	49	48	53	75	69
Hepatitis A	63	6	12	6	7	45	15	20
Hepatitis B, acute	9	11	8	6	8	4	4	3
Hepatitis C, acute	24	28	20	10	15	6	5	8
Influenza	1711	5529	2077	3703	8584	7408	14300	11668
incl. influenza A(H1N1)	0	16	136	5	169	1	35	197
Legionnaires' disease	3	10	8	6	14	16	18	12
Leptospirosis	5	2	2	2	3	5	6	5
Listeriosis	3	2	1	11	9	4	28	22
Malaria (imported)	6	3	3	4	1	2	3	3
Measles	4	2	0	4	2	1	10	27
Meningococcal disease, invasive	6	8	6	4	5	4	7	3
Mumps	4	12	10	3	4	6	6	4
Pertussis	149	55	43	77	74	56	69	135
Pneumococcal infection	104	110	66	90	143	160	195	220
Poliomyelitis	0	0	0	0	0	0	0	0
Q fever	0	0	0	0	0	0	0	0
Rabies	0	0	0	0	0	0	0	0
Rubella	0	2	0	0	0	0	0	0
Rubella, congenital	0	0	0	0	0	0	0	0
Salmonellosis	287	186	93	118	358	279	323	154
Shigellosis	34	12	10	12	17	16	17	29
Syphilis	41	38	34	25	27	37	24	40
Syphilis, congenital and neonatal	0	0	0	0	0	0	0	0
Tetanus	0	1	0	0	0	1	1	0
Toxoplasmosis, congenital	0	0	0	0	0	0	1	0
Trichinellosis	0	1	0	2	0	0	0	0
Tuberculosis, primary	183	226	200	166	163	144	120	125
Tularaemia	0	1	1	0	1	0	1	2
Typhoid/Paratyphoid fever	1/1	2/0	1/0	2/0	0/0	2/0	0/2	2/0

Diseases	Number of cases							
	2012	2013	2014	2015	2016	2017	2018	2019
Viral haemorrhagic fever with renal syndrome	19	19	22	14	11	25	15	26
West Nile fever	0	0	0	0	0	0	0	0
Yellow fever	0	0	0	0	0	0	0	0
Yersiniosis	47	72	62	53	45	43	63	42
Lyme disease	1546	1132	1289	1402	1420	1963	2284	2313
Tick-borne encephalitis	178	114	83	116	81	87	85	83

Confidence-Building Measure "C

Encouragement of publication of results and promotion of use of knowledge

No overview on publication of results and promotion of use of knowledge.

Confidence-Building Measure "E

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures ⁴	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	No	No	Yes	No
(b) Exports of micro-organisms ⁵ and toxins	No	No	Yes	No
(c) Imports of micro-organisms ¹¹ and toxins	No	No	Yes	No
(d) Biosafety ⁶ and biosecurity ⁷	Yes	Yes	No	No

⁴ Including guidelines.

⁵ Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

⁶ In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

⁷ In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

Exports of micro-organisms and toxins are regulated by the EC Council Regulation 1334/2000 and UN Recommendations of the United Nations Committee of Experts on the Transport of Dangerous Goods. Imports of micro-organisms and toxins are regulated by the EC Council Directives 94/55/EEC and 96/49/EEC.

Transport of dangerous biological substances is regulated by the WHO Guidance on regulations for the Transport of Infectious Substances, 2019-2020.

Estonian Health Board Guidance for the Transport of Infectious Substances, 2013.

EC Council Directive 2008/68/EC on the inland transport of dangerous goods.

Estonian Communicable Diseases Act 2003.

Biosafety is regulated by the Occupational Health and Safety Act 1999.

The occupational health and safety requirements for working environment affected by biological hazards established by the Government Decree No 144.

Biosafety regulations overlap with biosecurity; no specific biosecurity legislation exists.

Confidence-Building Measure "F"

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

There have not been any activities in offensive and/or defensive biological research and development programmes.

Confidence-Building Measure "G"

Form G

Declaration of vaccine production facilities

There are no vaccine production facilities in Estonia.